IIT-Kanpur’s Groundbreaking Discovery Gives Fresh Hope For Treating Brain Diseases And Cancer

IIT-Kanpur's Breakthrough in Biomedical Research Offers Hope for Brain Diseases and Cancer
IIT-Kanpur’s Groundbreaking Discovery Gives Fresh Hope For Treating Brain
Diseases And Cancer

With a study of G protein-coupled receptors (GPCRs) and chemokine receptor D6, the Indian Institute of Technology Kanpur (IIT-K) has made significant progress in biomedical research. This research offers new insights into the treatment of cancer and neurological conditions like schizophrenia, Parkinson's disease, and Alzheimer's disease.

By creating novel drug-like compounds to alter these receptors in illness situations, the study by the institute, according to a news release from IITK, facilitates understanding the possible therapy of cancer and brain disorders like Alzheimer's, Parkinson's, and schizophrenia. Since this study was published in the journal Science, it has received praise from all around the world.

To make sure this research effort was successful, researchers from all around the world collaborated with IIT-K. The research team consisted of Mohamed Chami from Basel, Switzerland; Tomasz Stepniewski and Jana Selent from Barcelona, Spain; Longhan Duan and Ka Young Chung from Suwon, Republic of Korea; and Fumia Sano, Wataru Shihoya, and Osamu Nureki from Tokyo, Japan.

The researchers produced intricate three-dimensional images of the receptors using a cutting-edge technique known as cryogenic-electron microscopy, or cryo-EM. This made it possible for them to closely examine the 3D molecular pictures of the receptors, which aided in the identification and development of novel drug-like compounds to address issues with these receptors that lead to disease states.

The results of this new study from IIT Kanpur will contribute to a better understanding of how these receptors function and help develop new therapeutic strategies and targeted treatments for diseases like cancer, which kills over 10 million people annually, and Alzheimer's disease, which affects over 50 million people globally. The development of novel drug-like compounds that can be evaluated for their therapeutic potential in animal models will now be made easier by the research's findings.

Related Stories

No stories found.